Boston Scientific's 2026 Guidance Praised as 'Reasonable' by RBC Analysts

jueves, 2 de abril de 2026, 11:09 am ET1 min de lectura
BSX--

Boston Scientific's (BSX) 2026 guidance is considered "reasonable" by RBC, but stock sentiment is driven by other factors. The guidance reflects the company's efforts to expand its product portfolio and increase revenue growth. The firm's upgrade to a "sector perform" rating indicates a neutral view of the stock.

Boston Scientific's 2026 Guidance Praised as 'Reasonable' by RBC Analysts

Comentarios



Add a public comment...
Sin comentarios

Aún no hay comentarios